Thu, Aug 21, 2014, 2:41 AM EDT - U.S. Markets open in 6 hrs 49 mins

Recent

% | $
Quotes you view appear here for quick access.

AbbVie Inc. Message Board

  • manumilitari_spqr manumilitari_spqr Jan 15, 2014 9:20 AM Flag

    AbbVie Announces Initiation of Pivotal Phase 3 Study of Veliparib (ABT-888) for Patients with Early-Stage Triple-Negative Breast Cancer

    NORTH CHICAGO, Ill., Jan. 15, 2014 /PRNewswire/ -- AbbVie (ABBV) today announced the initiation of a Phase 3 clinical trial
    evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888) when added to carboplatin, a chemotherapy, in women with early-stage, triple-negative breast cancer. The three-arm trial will compare the addition of veliparib plus carboplatin or placebo plus carboplatin to standard neoadjuvant chemotherapy.

 
ABBV
55.06-0.23(-0.42%)Aug 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.